arrow_back Back to App

Psychedelic Therapy for Veterans: New Research and Injury Treatment

This act aims to establish a grant program within the Department of Defense to research the use of psychedelic substances in treating service members suffering from PTSD, traumatic brain injury, and chronic traumatic encephalopathy. This initiative could provide veterans with access to new forms of therapy, potentially improving their quality of life and mental health.
Key points
The Department of Defense will create a grant program for psychedelic therapy research for service members.
Research will focus on treating post-traumatic stress, traumatic brain injury, and chronic traumatic encephalopathy.
Service members with these conditions will be able to participate in clinical trials using substances like MDMA or psilocybin.
Funding of $15 million annually for fiscal years 2024-2028 is authorized for this purpose.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3684
Sponsor: Rep. Crenshaw, Dan [R-TX-2]
Process start date: 2023-05-25
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Douglas Mike Day Psychedelic Therapy to Save Lives Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3684.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-05-25.

What are the main provisions?

Key points include:

  • The Department of Defense will create a grant program for psychedelic therapy research for service members.
  • Research will focus on treating post-traumatic stress, traumatic brain injury, and chronic traumatic encephalopathy.
  • Service members with these conditions will be able to participate in clinical trials using substances like MDMA or psilocybin.
  • Funding of $15 million annually for fiscal years 2024-2028 is authorized for this purpose.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Crenshaw, Dan [R-TX-2].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Armed Services.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Security